About
A small practice, deliberately
EpiSight exists because good epidemiological modeling is often commissioned by people who need an answer they can defend, and delivered by people who cannot explain how they got it.
We are a specialist consultancy, not a large firm. Engagements are handled directly by the person doing the modeling, which means you are never briefing an account manager and never receiving a deliverable that nobody in the room can fully explain. For larger projects we bring in collaborators from a network of academic epidemiologists and statisticians.
The methods we use come out of academic infectious disease epidemiology — the same models, fitted the same way, as the ones that appear in the peer-reviewed literature. What we add is a translation layer: framing the analysis around a decision, delivering it on a timeline that a business can act on, and being explicit about how much confidence the result can bear.
Founder
Stephen Kissler
(img/stephen.jpg)
Stephen Kissler is an infectious disease modeler and the founder of EpiSight. He is a faculty member at the University of Colorado Boulder, where his research focuses on the transmission dynamics of respiratory infections, viral kinetics, and how immunity and seasonality shape the timing of epidemics.
He completed his PhD in applied mathematics at the University of Cambridge and was a postdoctoral researcher in the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health. During the COVID-19 pandemic his group's work on transmission dynamics, viral shedding, and projected epidemic trajectories informed the response of public health agencies and was widely covered in the press.
His research has appeared in Science, The New England Journal of Medicine, and other peer-reviewed journals. EpiSight is his independent consulting practice and is not affiliated with the University of Colorado.
Selected work
Published research
Client engagements are confidential, so the public record of our methods is the peer-reviewed literature they are built on.
Full publication list on Google Scholar (opens in a new tab)
- Projecting the transmission dynamics of SARS-CoV-2 through the post-pandemic period (opens in a new tab) Multi-year incidence projection under scenarios for immunity and seasonality — the method behind our burden work.
- Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies (opens in a new tab) The framework for estimating viral trajectories from longitudinal testing data that underpins our within-host work.
- Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons (opens in a new tab) How vaccination and variant change the shape of an infection — the question a therapeutic developer asks of its own product.
- Viral kinetics of sequential SARS-CoV-2 infections (opens in a new tab) How prior infection reshapes subsequent kinetics, and what that means for interpreting a viral load endpoint.
- Characterizing SARS-CoV-2 viral clearance kinetics to improve the design of antiviral pharmacometric studies (opens in a new tab) Using viral kinetics to inform how an antiviral trial should be designed and powered.
- Drivers of geographic patterns in outpatient antibiotic prescribing in the United States (opens in a new tab) Large-scale claims analysis of how antibiotics are actually prescribed, and what explains the variation.
Let's talk about your question.
Initial conversations are free and genuinely exploratory. We will tell you honestly whether modeling would help.
Get in touch